Chemoreflex Sensitivity in Chronic Kidney Disease

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00794872
• Date of registration: 19/11/2008
• Primary sponsor: RWTH Aachen University
• Public title: Chemoreflex Sensitivity in Chronic Kidney Disease
• Scientific title: Hyperoxic Chemoreflex Sensitivity in Chronic Kidney Disease
• Date of first enrolment: January 2007
• Target sample size: 65
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00794872
• Study type: Observational
• Study design: Observational Model: Cohort, Time Perspective: Prospective

Countries of recruitment

Germany

Contacts

• Name: Christian Meyer, MD
• Affiliation: RWTH Aachen University Departement of Cardiology, Pulmonology and Vascular Medicine

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients suffering from CDK stage 3 (GFR 30-59 ml/min/1.73 m²) or stage 4 (GFR 15-29
ml/min/1.73 m²)

- For the reference Patients without evidence for CDK

Exclusion Criteria:

- Patients with heart failure, history of myocardial infarction or instable angina
pectoris, atrial fibrillation, hyperthyroidism, chronic pulmonary diseases, sleep
apnoea syndrome, alcohol abuse and drug induced cardiomyopathy



Age minimum: 18 Years
Age maximum: 90 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Cardiovascular Morbidity

Chronic Kidney Disease

Intervention(s)

Other: blood sampling

Primary Outcome(s)

Hyperoxic chemoreflex sensitivity is impaired in patients with moderate to severe chronic kidney disease [Time Frame: No]

Secondary ID(s)

Chemoreflex-Sensitivity-Study

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Heinrich-Heine University, Duesseldorf

Medical Clinic I, SLK-Kliniken Heilbronn